Zolpidem for the Treatment of Dystonia

Frontiers in Neurology
Stephanie Patricia J Badillo, Roland Dominic G Jamora

Abstract

Background and Purpose: There are recent reports of zolpidem being effective for the treatment of a variety of movement disorders, due to its action on the gamma-aminobutyric acid A receptors in the thalamus, subthalamic nucleus, and globus pallidus, hence facilitating inhibitory pathways in the basal ganglia motor loop. Its beneficial effects have been described for Parkinson's disease and other related disorders. The objective of this study was to assess the therapeutic effects of zolpidem for various types of dystonia. Methods: We conducted a literature search using MEDLINE via PubMed, Cochrane Library, EMBASE, Scopus, and Google Scholar. Results: There were no randomized controlled trials. The literature included 6 case reports, 4 case series, and 1 non-randomized, non-controlled interventional trial. Overall, 49 adult participants (range 1-34 participants) with a mean age of 49.5 years were treated. Regardless of the dystonia subtype, a single dose of zolpidem at 10 mg causes improvement of symptoms for a mean duration of 3.4 h until patient returns to baseline. The main adverse effect noted was drowsiness, which was dose-dependent. Conclusion: While the current available literature suggests that zolpidem may be an effecti...Continue Reading

References

Sep 1, 1995·Clinical Pharmacokinetics·P Salvà, J Costa
Apr 26, 1997·Lancet·A DanieleP Bartolomeo
Apr 30, 1999·Journal of Psychopharmacology·G DarcourtJ Lavoisy
Aug 14, 1999·The New England Journal of Medicine·A DanieleA R Bentivoglio
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·E RůzickaP Busek
Apr 17, 2001·The Annals of Pharmacotherapy·D K Farver, M H Khan
Mar 8, 2002·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Brigitte J MayrFranz Reisecker
Sep 17, 2002·European Journal of Pharmacology·Enrico SannaGiovanni Biggio
Mar 7, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Cynthia L ComellaUNKNOWN and The Dystonia Study Group
Mar 18, 2004·Experimental Neurology·Lei ChenWing-Ho Yung
Aug 10, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Nélida Susana GarrettoMarcela Mancuso
Oct 19, 2004·Lancet Neurology·Giovanni DefazioAlfredo Berardelli
Mar 6, 2007·Neuroscience Research·Lei ChenWing-Ho Yung
May 20, 2008·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Yen-Yu ChenShey-Lin Wu
Jun 27, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Jae Young AnKwang Soo Lee
Sep 8, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·In-Seok ParkKwang-Soo Lee
Dec 17, 2009·Expert Opinion on Pharmacotherapy·Leslie J Cloud, H A Jinnah
Jan 15, 2010·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·C CotterD Crimmins
Jan 20, 2011·The International Journal of Neuroscience·Roland Dominic G JamoraLillian V Lee
Apr 25, 2012·Frontiers in Neurology·Yoshimichi MiyazakiRyuji Kaji
Nov 2, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Thomas D SteevesTamara Pringsheim
May 3, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Olga Waln, Joseph Jankovic
May 8, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Alberto AlbaneseJan K Teller
Jun 14, 2013·Case Reports in Neurological Medicine·Sandip K Dash
May 1, 2011·Journal of Movement Disorders·Munkyung SunwooSun-Ah Choi
Nov 6, 2014·Case Reports in Medicine·Andrew Young Chang, Erica Weirich
Dec 3, 2014·Parkinsonism & Related Disorders·Daniel Martinez-RamirezRamon L Rodriguez
Jun 28, 2017·JAMA Neurology·Martin N BomalaskiMark D Peterson
Dec 18, 2015·Movement Disorders Clinical Practice·Yoshimichi MiyazakiRyuji Kaji

❮ Previous
Next ❯

Citations

Aug 7, 2020·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C DelormeF Mochel
Apr 21, 2021·Journal of Neural Transmission·Michelle Ann C Sy, Hubert H Fernandez
Apr 28, 2021·Expert Opinion on Pharmacotherapy·Marina SvetelVladimir Kostić
Dec 4, 2019·Clinical Parkinsonism & Related Disorders·Steven Bellows, Joseph Jankovic

❮ Previous
Next ❯

Methods Mentioned

BETA
Sedation

Software Mentioned

Scopus
MEDLINE
Cochrane
EMBASE
Google Scholar

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.